- Home
- GNFT vs ABEO Comparison
GNFT vs ABEO Comparison
Compare GNFT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- ABEO
- Stock Information
- Founded
- GNFT 1999
- ABEO N/A
- Country
- GNFT France
- ABEO United States
- Employees
- GNFT N/A
- ABEO N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- ABEO Health Care
- Exchange
- GNFT Nasdaq
- ABEO Nasdaq
- Market Cap
- GNFT 190.6M
- ABEO 247.8M
- IPO Year
- GNFT 2019
- ABEO 1980
- Fundamental
- Price
- GNFT $3.81
- ABEO $5.56
- Analyst Decision
- GNFT Strong Buy
- ABEO Strong Buy
- Analyst Count
- GNFT 1
- ABEO 3
- Target Price
- GNFT $13.00
- ABEO $18.00
- AVG Volume (30 Days)
- GNFT 7.8K
- ABEO 177.7K
- Earning Date
- GNFT 09-19-2024
- ABEO 11-14-2024
- Dividend Yield
- GNFT N/A
- ABEO N/A
- EPS Growth
- GNFT N/A
- ABEO N/A
- EPS
- GNFT 0.47
- ABEO N/A
- Revenue
- GNFT $86,225,222.00
- ABEO N/A
- Revenue This Year
- GNFT $155.44
- ABEO N/A
- Revenue Next Year
- GNFT N/A
- ABEO $18,714.71
- P/E Ratio
- GNFT $7.69
- ABEO N/A
- Revenue Growth
- GNFT 175.45
- ABEO 147.52
- 52 Week Low
- GNFT $3.31
- ABEO $3.05
- 52 Week High
- GNFT $6.42
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- GNFT 32.66
- ABEO 34.07
- Support Level
- GNFT $3.63
- ABEO $5.45
- Resistance Level
- GNFT $3.76
- ABEO $5.79
- Average True Range (ATR)
- GNFT 0.12
- ABEO 0.18
- MACD
- GNFT 0.04
- ABEO -0.02
- Stochastic Oscillator
- GNFT 18.77
- ABEO 20.34
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.